Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13089805 | 0.85 | MET (0.57) | MET | |
| SCHEMBL3067317 | 0.82 | MET (0.61) | METHDAC1GCGRIRAK1IRAK4 | |
| SCHEMBL3070654 | 0.82 | MET (0.59) | MET | |
| SCHEMBL13089762 | 0.81 | MET (0.56) | METHDAC1GCGRIRAK1IRAK4 | |
| SCHEMBL3062465 | 0.79 | MET (0.64) | METHDAC1IRAK1IRAK4 | |
| SCHEMBL1302876 | 0.79 | MET (0.59) | METHDAC1GCGRIRAK1IRAK4 | |
| SCHEMBL13089799 | 0.78 | MET (0.66) | METHDAC1IRAK1IRAK4 | |
| SCHEMBL1952612 | 0.78 | MET (0.60) | METHDAC1IRAK1IRAK4 | |
| SCHEMBL3062334 | 0.77 | MET (0.59) | METHDAC1IRAK1IRAK4 | |
| SCHEMBL2471211 | 0.77 | MET (0.75) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221806-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| EP-2049531-B1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-8435981-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2008017361-A2 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885HDAC1 745/4885GCGR 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.